Helle Pappot

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. ncbi [Lung cancer--a technological challenge II. New approaches to treatment]
    Helle Pappot
    H:S Rigshospitalet, Finsencentret, Onkologisk Klinik,
    Ugeskr Laeger 166:4243-5. 2004
  2. ncbi The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis
    Helle Pappot
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Lung Cancer 51:193-200. 2006
  3. ncbi [Lung cancer--a technological challenge I. Diagnostics and staging]
    Trine Jakobi Nøttrup
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4241-3. 2004
  4. ncbi Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Charlotte Elberling Almasi
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK-2100, Denmark
    Lung Cancer 48:349-55. 2005
  5. ncbi Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer
    Line V Hansen
    The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark
    Lung Cancer 58:260-6. 2007
  6. ncbi Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer
    Charlotte Elberling Almasi
    Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloesvej 5, Copenhagen N, Denmark
    APMIS 117:755-61. 2009
  7. ncbi [Women and lung cancer--epidemiology, smoking and biology]
    Barbara Malene Fischer
    H:S Rigshospitalet, Finsen Centret,
    Ugeskr Laeger 165:4550-2. 2003
  8. ncbi Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival
    Birgit Guldhammer Skov
    Department of Pathology, Herlev Hospital, Division Gentofte, Niels Andersens Vej 65, 2900 Copenhagen, Hellerup, Denmark
    Lung Cancer 59:88-94. 2008

Collaborators

  • Barbara M Fischer
  • Halla Skuladottir
  • Charlotte Elberling Almasi
  • Birgit Guldhammer Skov
  • Ib Jarle Christensen
  • Line V Hansen
  • Trine Jakobi Nøttrup
  • Gunilla Høyer-Hansen
  • Birgit G Skov
  • Michael Ploug

Detail Information

Publications8

  1. ncbi [Lung cancer--a technological challenge II. New approaches to treatment]
    Helle Pappot
    H:S Rigshospitalet, Finsencentret, Onkologisk Klinik,
    Ugeskr Laeger 166:4243-5. 2004
  2. ncbi The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis
    Helle Pappot
    The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    Lung Cancer 51:193-200. 2006
    ..To understand these interactions and the clinical importance of the tissue levels of uPA, PAI-1 and uPA-PAI-1 complex, the results suggest further exploratory studies of the components in pulmonary adenocarcinomas and other cancers...
  3. ncbi [Lung cancer--a technological challenge I. Diagnostics and staging]
    Trine Jakobi Nøttrup
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:4241-3. 2004
  4. ncbi Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue
    Charlotte Elberling Almasi
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen DK-2100, Denmark
    Lung Cancer 48:349-55. 2005
    ..7, P=0.002) and tumour size (HR 2.4, P=0.02). CONCLUSION: uPAR(I) levels in the extracts of primary tumours independently predicted overall survival of 63 patients with SCC...
  5. ncbi Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer
    Line V Hansen
    The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark
    Lung Cancer 58:260-6. 2007
    ..4A expression. In the present study, we therefore explored the possible association between C4.4A expression and prognosis in patients with non-small cell lung cancer (NSCLC)...
  6. ncbi Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer
    Charlotte Elberling Almasi
    Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloesvej 5, Copenhagen N, Denmark
    APMIS 117:755-61. 2009
    ..3, 2.8 and 3.8 respectively). High blood levels of intact uPAR and its cleaved forms are associated with poor prognosis in NSCLC...
  7. ncbi [Women and lung cancer--epidemiology, smoking and biology]
    Barbara Malene Fischer
    H:S Rigshospitalet, Finsen Centret,
    Ugeskr Laeger 165:4550-2. 2003
  8. ncbi Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival
    Birgit Guldhammer Skov
    Department of Pathology, Herlev Hospital, Division Gentofte, Niels Andersens Vej 65, 2900 Copenhagen, Hellerup, Denmark
    Lung Cancer 59:88-94. 2008
    ..We examined the expression of ERalpha, ERbeta and progesterone in a well defined cohort of patients with NSCLC with more than 15 years of follow up, and related the results to gender and survival...